New Viresolve(R) Pro+ Solution addresses increasingly difficult
virus-removal challenges
BILLERICA, Mass.--(BUSINESS WIRE)--
Millipore
Corporation (NYSE:MIL), a leading provider of technologies, tools
and services for the global life science industry, today announced the
availability of its new Viresolve(R)
Pro+ Solution, an innovative virus filtration product that further
extends the company's leadership in the rapidly growing and highly
regulated virus safety market. Millipore made the announcement at the 28th
Annual J.P. Morgan Healthcare Conference in San Francisco, California.
"Virus safety is an increasingly critical issue in the biopharmaceutical
industry and recent incidents of viral contamination have highlighted
why effective virus safety solutions are so important for our
customers," said Jean-Paul Mangeolle, President of Millipore's
Bioprocess Division. "The launch of Viresolve Pro+ Solution expands our
industry-leading virus safety offerings, which help companies address
increasingly diverse and difficult virus-removal challenges, improve the
productivity of their manufacturing processes, and ensure the safety and
quality of their products."
Biological drug products such as monoclonal antibodies and therapeutic
proteins are manufactured using biological source material and
production processes that can become contaminated with viruses. As a
result, biopharmaceutical manufacturers are required to incorporate
sufficient virus clearance steps into their manufacturing processes to
ensure their products are free of virus contamination.
Millipore's virus safety products provide customers with effective and
robust virus filtration, from process development to full-scale
biopharmaceutical production. Viresolve Pro+ Solution strengthens
Millipore's offerings by providing a robust parvovirus clearance that
works effectively at higher titer feedstreams. Parvoviruses are some of
the smallest viruses found in nature, which makes them particularly
difficult to remove in the manufacturing process.
Viresolve Pro+ Solution is available in a disposable flow path and
increases the overall capacity and productivity of biopharmaceutical
manufacturers' virus removal operations. It is designed to fit both
monoclonal antibody and therapeutic protein processes. It also includes
a proprietary binary gas integrity test (BGT) to detect the presence of
oversized pores or defects that can compromise a filter's retention
capability and cause contamination in the end product--providing a
critical quality-control safeguard for the end user.
"As we continue to launch more innovative virus products, we're
leveraging our product breadth and applications expertise to offer
customers complete virus safety solutions," noted Paul Chapman,
Millipore's Vice President, Downstream Processing. "Later this year
we'll introduce additional validation services and turn-key solutions to
help our customers address their complex virus safety challenges."
About Millipore:
Millipore (NYSE: MIL) is a Life Science leader providing cutting-edge
technologies, tools, and services for bioscience research and
biopharmaceutical manufacturing. As a strategic partner, we collaborate
with customers to confront the world's challenging human health issues.
From research to development to production, our scientific expertise and
innovative solutions help customers tackle their most complex problems
and achieve their goals. Millipore Corporation is an S&P 500 company
with more than 5,900 employees worldwide. For more information, please
contact Millipore Tech Service at 1-800-548-7853 or 951-676-8080 or
visit www.millipore.com.
ADVANCING LIFE SCIENCE TOGETHER(R)
Research. Development. Production.
Forward Looking Statements:
The matters discussed herein, as well as in future oral and written
statements by management of Millipore Corporation that are
forward-looking statements, are based on current management expectations
that involve substantial risks and uncertainties which could cause
actual results to differ materially from the results expressed in, or
implied by, these forward-looking statements.
Potential risks and uncertainties that could affect Millipore's
future operating results include, without limitation, failure to achieve
design wins into our pharmaceutical and biotechnology customers'
manufacturing design phase for a particular drug; delay, suspension or
termination of a customer's volume production; lack of availability of
raw materials or component products on a timely basis; regulatory delay
in the approval of customers' therapeutics; limitations on cash flow
available for operations and investment due to increased debt service
obligations; the inability to establish and maintain necessary product
and process quality levels; reduced demand for animal-derived cell
culture products; the inability to realize the expected benefits of
development, marketing, licensing and other alliances; competitive
factors such as new membrane or chromatography technology; the inability
to achieve anticipated cost benefits of our supply chain initiatives;
risks relating to our concentration of principal manufacturing
operations; the inability to utilize technology in current or planned
products due to overriding rights by third parties; potential
environmental liabilities; conditions in the economy in general and in
the bioscience and bioprocess markets in particular; foreign exchange
fluctuations; reduced private and government research funding; exposure
to product liability claims; and difficulties inherent in transferring
or outsourcing of manufacturing operations. Please refer to our filings
with the SEC, including our most recent Annual Report on Form 10-K, for
more information on these and other risks that could cause actual
results to differ.
Millipore, Viresolve and ADVANCING LIFE SCIENCE TOGETHER are registered
trademarks; the "M" logo is a trademark of Millipore Corporation.
Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6136671&lang=en
Source: Millipore Corporation
